Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Voyager Therapeutics, Inc. (VYGR : NSDQ)
 
 • Company Description   
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Number of Employees: 172

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.93 Daily Weekly Monthly
20 Day Moving Average: 359,201 shares
Shares Outstanding: 55.60 (millions)
Market Capitalization: $218.51 (millions)
Beta: 1.28
52 Week High: $6.27
52 Week Low: $2.65
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.66% -9.50%
12 Week -23.69% -24.92%
Year To Date 0.00% 0.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
75 HAYDEN AVENUE
-
LEXINGTON,MA 02421
USA		 ph: 857-259-5340
fax: -		 investors@voyagertherapeutics.com http://www.voyagertherapeutics.com
 
 • General Corporate Information   
Officers
Alfred Sandrock - Chief Executive Officer; President; and Director
Michael Higgins - Chairman
Nathan Jorgensen - Chief Financial Officer
Grace E. Colon - Director
James Geraghty - Director

Peer Information
Voyager Therapeutics, Inc. (CORR.)
Voyager Therapeutics, Inc. (RSPI)
Voyager Therapeutics, Inc. (CGXP)
Voyager Therapeutics, Inc. (BGEN)
Voyager Therapeutics, Inc. (GTBP)
Voyager Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92915B106
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/10/26
Share - Related Items
Shares Outstanding: 55.60
Most Recent Split Date: (:1)
Beta: 1.28
Market Capitalization: $218.51 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.39 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/10/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.99
Price/Cash Flow: -
Price / Sales: 6.98
EPS Growth
vs. Year Ago Period: -193.75%
vs. Previous Quarter: 17.54%
Sales Growth
vs. Year Ago Period: -45.73%
vs. Previous Quarter: 157.02%
ROE
12/31/25 - -
09/30/25 - -48.94
06/30/25 - -37.65
ROA
12/31/25 - -
09/30/25 - -37.38
06/30/25 - -28.89
Current Ratio
12/31/25 - -
09/30/25 - 6.19
06/30/25 - 5.43
Quick Ratio
12/31/25 - -
09/30/25 - 6.19
06/30/25 - 5.43
Operating Margin
12/31/25 - -
09/30/25 - -404.85
06/30/25 - -253.49
Net Margin
12/31/25 - -
09/30/25 - -404.85
06/30/25 - -253.49
Pre-Tax Margin
12/31/25 - -
09/30/25 - -402.55
06/30/25 - -251.89
Book Value
12/31/25 - -
09/30/25 - 3.96
06/30/25 - 4.41
Inventory Turnover
12/31/25 - -
09/30/25 - -
06/30/25 - -
Debt-to-Equity
12/31/25 - -
09/30/25 - 0.00
06/30/25 - 0.00
Debt-to-Capital
12/31/25 - -
09/30/25 - 0.00
06/30/25 - 0.00
 

Powered by Zacks Investment Research ©